BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 36165723)

  • 1. Therapeutic Targeting of FGFR Signaling in Head and Neck Cancer.
    Wang Z; Anderson KS
    Cancer J; 2022 Sep-Oct 01; 28(5):354-362. PubMed ID: 36165723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibroblast growth factor (FGF), FGF receptor (FGFR), and cyclin D1 (CCND1) DNA methylation in head and neck squamous cell carcinomas is associated with transcriptional activity, gene amplification, human papillomavirus (HPV) status, and sensitivity to tyrosine kinase inhibitors.
    Bao Y; Gabrielpillai J; Dietrich J; Zarbl R; Strieth S; Schröck F; Dietrich D
    Clin Epigenetics; 2021 Dec; 13(1):228. PubMed ID: 34933671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [FGFR-targeted therapy in head and neck carcinomas].
    Dietrich D
    HNO; 2021 Mar; 69(3):172-184. PubMed ID: 32519203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
    Koole K; Brunen D; van Kempen PM; Noorlag R; de Bree R; Lieftink C; van Es RJ; Bernards R; Willems SM
    Clin Cancer Res; 2016 Aug; 22(15):3884-93. PubMed ID: 26936917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibroblast growth factor family aberrations as a putative driver of head and neck squamous cell carcinoma in an epidemiologically low-risk patient as defined by targeted sequencing.
    Tillman BN; Yanik M; Birkeland AC; Liu CJ; Hovelson DH; Cani AK; Palanisamy N; Carskadon S; Carey TE; Bradford CR; Tomlins SA; McHugh JB; Spector ME; Brenner JCh
    Head Neck; 2016 Apr; 38 Suppl 1(Suppl 1):E1646-52. PubMed ID: 26849095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells.
    Marshall ME; Hinz TK; Kono SA; Singleton KR; Bichon B; Ware KE; Marek L; Frederick BA; Raben D; Heasley LE
    Clin Cancer Res; 2011 Aug; 17(15):5016-25. PubMed ID: 21673064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications.
    Helsten T; Schwaederle M; Kurzrock R
    Cancer Metastasis Rev; 2015 Sep; 34(3):479-96. PubMed ID: 26224133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome-wide open reading frame profiling identifies fibroblast growth factor signaling as a driver of PD-L1 expression in head and neck squamous cell carcinoma.
    Mann JE; Smith JD; Kulkarni A; Foltin SK; Scheftz EB; Murray IR; Gensterblum-Miller E; Brummel CV; Bhangale A; Hoesli RC; Brenner JC
    Oral Oncol; 2023 Nov; 146():106562. PubMed ID: 37666053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma.
    Kono M; Komatsuda H; Yamaki H; Kumai T; Hayashi R; Wakisaka R; Nagato T; Ohkuri T; Kosaka A; Ohara K; Kishibe K; Takahara M; Katada A; Hayashi T; Kobayashi H; Harabuchi Y
    Oncoimmunology; 2022; 11(1):2021619. PubMed ID: 35003900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibroblast Growth Factor Receptor Family Members as Prognostic Biomarkers in Head and Neck Squamous Cell Carcinoma: A Systematic Review.
    Ipenburg NA; Koole K; Liem KS; van Kempen PM; Koole R; van Diest PJ; van Es RJ; Willems SM
    Target Oncol; 2016 Feb; 11(1):17-27. PubMed ID: 26115874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
    Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
    Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics.
    Parish A; Schwaederle M; Daniels G; Piccioni D; Fanta P; Schwab R; Shimabukuro K; Parker BA; Helsten T; Kurzrock R
    Cell Cycle; 2015; 14(13):2121-8. PubMed ID: 25950492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors.
    Hierro C; Rodon J; Tabernero J
    Semin Oncol; 2015 Dec; 42(6):801-19. PubMed ID: 26615127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas.
    Seiwert TY; Zuo Z; Keck MK; Khattri A; Pedamallu CS; Stricker T; Brown C; Pugh TJ; Stojanov P; Cho J; Lawrence MS; Getz G; Brägelmann J; DeBoer R; Weichselbaum RR; Langerman A; Portugal L; Blair E; Stenson K; Lingen MW; Cohen EE; Vokes EE; White KP; Hammerman PS
    Clin Cancer Res; 2015 Feb; 21(3):632-41. PubMed ID: 25056374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions.
    Repetto M; Crimini E; Giugliano F; Morganti S; Belli C; Curigliano G
    Expert Rev Clin Pharmacol; 2021 Oct; 14(10):1233-1252. PubMed ID: 34591728
    [No Abstract]   [Full Text] [Related]  

  • 16. FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers.
    Göke F; Franzen A; Hinz TK; Marek LA; Yoon P; Sharma R; Bode M; von Maessenhausen A; Lankat-Buttgereit B; Göke A; Golletz C; Kirsten R; Boehm D; Vogel W; Kleczko EK; Eagles JR; Hirsch FR; Van Bremen T; Bootz F; Schroeck A; Kim J; Tan AC; Jimeno A; Heasley LE; Perner S
    Clin Cancer Res; 2015 Oct; 21(19):4356-64. PubMed ID: 26015511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FGF19 amplification reveals an oncogenic dependency upon autocrine FGF19/FGFR4 signaling in head and neck squamous cell carcinoma.
    Gao L; Lang L; Zhao X; Shay C; Shull AY; Teng Y
    Oncogene; 2019 Mar; 38(13):2394-2404. PubMed ID: 30518874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of fibroblasts reduced head and neck cancer growth by targeting fibroblast growth factor receptor.
    Sweeny L; Liu Z; Lancaster W; Hart J; Hartman YE; Rosenthal EL
    Laryngoscope; 2012 Jul; 122(7):1539-44. PubMed ID: 22460537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of fibroblast growth factor receptor 1 (FGFR1) amplification in squamous cell carcinomas of the head and neck.
    Clauditz TS; Böttcher A; Hanken H; Borgmann K; Sauter G; Wilczak W; Grob T; Münscher A
    J Cancer Res Clin Oncol; 2018 Jan; 144(1):53-61. PubMed ID: 29022097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting VEGFR and FGFR in head and neck squamous cell carcinoma in vitro.
    Brands RC; Knierim LM; De Donno F; Steinacker V; Hartmann S; Seher A; Kübler AC; Müller-Richter UDA
    Oncol Rep; 2017 Sep; 38(3):1877-1885. PubMed ID: 28714017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.